Live Breaking News & Updates on Michael Pehl

Stay updated with breaking news from Michael pehl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adcendo funding boosts antibody-drug conjugates development

Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP - News - PharmaTimes ....

Michael Pehl , Novo Holdings , Pontifax Venture Capital , Ysios Capital , Gilde Healthcare , Ohad Hammer ,

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

/PRNewswire/ Duality Biologics ("Duality"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates. ....

John Zhu , Michael Pehl , Novo Holdings , Duality Immune Toxin Antibody Conjugates , Adcendo Aps , Duality Immune Modulating Antibody Conjugates , Ysios Capital , Duality Biologics ,

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality's DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC programAgreement based on synergies between Adcendo and Duality in ....

John Zhu , Kostenloser Wertpapierhandel , Michael Pehl , Novo Holdings , Duality Immune Toxin Antibody Conjugates , Duality Biologics , Chief Executive Officer , Ysios Capital , Duality Immune Modulating Antibody Conjugates ,

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of. ....

Dominik Mumberg , Carmelm Lynch , Michael Pehl , Dennis Benjamin , Bayer Ag , Finsen Laboratory , University Of Copenhagen , University Of Marburg , Apoptosis Signal Transduction Research At Schering , Head Of Therapeutic Research Area Oncology , Stanford Executive Program , University Of Chicago , Novo Holdings , Chief Scientific Officer , Therapeutic Research Area Oncology , Targeted Alpha Therapies , Translational Innovation , Signal Transduction Research , Molecular Biology , Chief Executive Officer , Chief Development Officer , Chief Technology Officer , Research Fellow , Scientific Advisory Board , Adcendo Aps , Ysios Capital ,

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

/PRNewswire/ Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers,. ....

Carmel Lynch , Carmelm Lynch , Michael Pehl , Dennis Benjamin , Bioinnovation Institute , Finsen Laboratory , University Of Copenhagen , Praecis Pharmaceuticals , University College Dublin , Global Product Development , Research At Seattle Genetics , Company As Research , Health Canada , Novo Holdings , Fred Hutchinson Cancer Research Center , Novo Nordisk , Chief Development Officer , Chief Technology Officer , Research Fellow , Scientific Advisory Board , Chief Executive Officer , Clinical Pharmacology , Biophysical Chemistry , Seattle Genetics , Ysios Capital , Gilde Healthcare ,